Identification of Key Blood Molecular Markers for Immunotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

191 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-07-06

Study Completion Date

2015-02-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To identify unique blood markers in cancer patients so that we can identify patients with evidence of pre-existing immunity who may be a responder to immunotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

NCT05334069

Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Ann Arbor Stage I Lymphoma +59 more

RECRUITING

Studying Biomarkers in Tumor Tissue and Blood Samples From Patients With Small Cell Lung Cancer Registered on CALGB-140202

NCT01503619

Lung Cancer

COMPLETED

Evaluation of Preexisting Immunity Markers in Human Tumor Tissue Sample

NCT00568867

Cancer

COMPLETED

Permission to Collect Blood Over Time for Research

NCT00767234

Pancreatic Cancer Gastrointestinal Neoplasms Colon Rectal Cancer Adenocarcinoma +11 more

TERMINATED

Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

NCT00349830

Carcinomas (Including Squamous Cell and Adenocarcinoma) Neoplasms

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Squamous Cell Carcinoma Adenocarcinoma Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

phlebotomy

Standard of care

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

blood draw

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients diagnosed with cancerous tumors based on biopsy or other clinical observations.
2. Patients diagnosed with non-cancerous tumors based on biopsy or other clinical observations.
3. Normal volunteers who do not have cancer or other medical conditions that may affect survival.

Exclusion Criteria

1. Patients will be excluded if, upon clinical observation, they are under a severe septic or inflammatory condition. In these conditions, human body immune response against sepsis or inflammation should be the predominant response, and may shield or block the immune response against tumors.
2. Patients will be excluded if, upon clinical observation, they are under extremely illness situation like myocardial infarction. In such a case, the immune findings may be altered.
3. Patients will be excluded if, upon looking through their medical records, significant information required for data analysis is missing. This is because that patients' medical records will help us connect our research findings with their clinical observations, and further provide guidelines for subsequent treatment options.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No